Lymphoma, B-Cell: all 1,415 studies
Page 4 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingNCT04792502Phase 2
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingNCT04792489Phase 2
- Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell LymphomaRecruitingNCT04715217Phase 1/2
- Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st LineRecruitingNCT04670029Phase 3
- Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCLNot yet recruitingNCT04659434Phase 2
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- UCD19 CarT in Treatment of Pediatric B-ALL and B-NHLRecruitingNCT04544592Phase 1/2
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
- Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by ImmunochemotherapyRecruitingNCT04442412Phase 3
- Multi-CAR-T Cells Targeting B Cell LymphomasNot yet recruitingNCT04429438Phase 1/2
- A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell LymphomaRecruitingNCT04332822Phase 3
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- Study of CAR-T Therapy in Older PatientsRecruitingNCT04300998
- Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT04300101
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- Cell Free DNA in Mature B-cell LymphomaRecruitingNCT04088422
- A Study in Leukemia Patients With KaronudibRecruitingNCT04077307Phase 1
- Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaRecruitingNCT04058470Phase 1/2
- Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT03936153Phase 2
- A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma PatientsRecruitingNCT03650933Phase 3
- A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell LymphomaEnrolling by invitationNCT03383406Phase 2
- Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
- The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell LymphomaRecruitingNCT02449278Phase 3
- Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell LymphomaRecruitingNCT02449265Phase 3
- Family Study of Lymphoproliferative DisordersRecruitingNCT00626496
- Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)CompletedNCT06004167Not applicableResults posted
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasActive, not recruitingNCT05583149Phase 2Results posted
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)TerminatedNCT05328102Phase 2Results posted
- An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaTerminatedNCT05315713Phase 1/2Results posted
- A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT05144009Phase 2Results posted
- A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT05121103Phase 1Results posted
- Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient SettingCompletedNCT05108805Phase 4Results posted
- A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT05023980Phase 3Results posted
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT05020015Phase 2Results posted
- Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05008055Phase 2Results posted
- Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasTerminatedNCT04933617Phase 1Results posted
- A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
- Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell LymphomaCompletedNCT04836195Phase 1Results posted
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Phase 3Results posted
- Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
- FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLCompletedNCT04555811Phase 1Results posted
- ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedNCT04517435Phase 1/2Results posted
- Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
- Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedNCT04432506Phase 2Results posted
- Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell TherapyCompletedNCT04359784Phase 2Results posted
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedNCT04358458Phase 1/2Results posted
- 18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaCompletedNCT04317313Results posted
- A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)CompletedNCT04317066Phase 1Results posted
- Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedNCT04314843Phase 1Results posted
- A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaCompletedNCT04313608Phase 1Results posted
- Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
- Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
- T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLCompletedNCT04134936Phase 1Results posted
- Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell MalignanciesCompletedNCT04088890Phase 1Results posted
- Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasCompletedNCT04074746Phase 1/2Results posted
- A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)TerminatedNCT04035434Phase 1/2Results posted
- Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLCompletedNCT04030195Phase 1/2Results posted
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT03992339Phase 2Results posted
- CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)Active, not recruitingNCT03774654Phase 1Results posted
- Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedNCT03761056Phase 2Results posted
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2Results posted
- A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT03743246Phase 1/2Results posted
- Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaCompletedNCT03742258Phase 1Results posted
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedNCT03704298Phase 1Results posted
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaActive, not recruitingNCT03696784Phase 1Results posted
- Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
- Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
- A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaCompletedNCT03677141Phase 1/2Results posted
- Mobile Health Case Management System for Reducing Pediatric Treatment AbandonmentCompletedNCT03677128Not applicableResults posted
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)TerminatedNCT03645395Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT03589469Phase 2Results posted
- Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03583424Phase 1/2Results posted
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular LymphomaTerminatedNCT03571828Phase 1Results posted
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin LymphomaCompletedNCT03570892Phase 3Results posted
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
- Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy TreatmentActive, not recruitingNCT03505762Phase 2Results posted
- PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT03488251Phase 2Results posted
- Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)CompletedNCT03483103Phase 2Results posted
- Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationCompletedNCT03456726Phase 2Results posted
- PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
- DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 2Results posted
- Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03340766Phase 1Results posted
- Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
- Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaCompletedNCT03309878Phase 1/2Results posted
- Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)TerminatedNCT03298412Phase 2Results posted
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasActive, not recruitingNCT03277729Phase 1/2Results posted
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™CompletedNCT03263026Phase 3Results posted
- Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasCompletedNCT03255018Phase 2Results posted
- Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
- A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
- Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.Active, not recruitingNCT03150329Phase 1Results posted
- Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
- A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT03136497Phase 1Results posted
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedNCT03133221Phase 2Results posted